BioStock: Saniona raises capital to advance epilepsy programme

Saniona’s CEO Thomas Feldthus visited BioStock’s studio for an interview discussing the company’s drug development pipeline with epilepsy candidate SAN711 leading the way. We also learn more about the ongoing rights issue of approximately SEK 140 million and how Saniona plans on using the proceeds.

Watch the interview with Saniona's CEO Thomas Feldthus at biostock.se:

Saniona raises capital to advance epilepsy programme - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/